Pathalys Pharma: $105 Million (Series B) Raised To Develop Treatments For Kidney Disease
By Amit Chowdhry ● Aug 23, 2024
Pathalys Pharma, a private biopharmaceutical company in the late stages of developing treatments for kidney disease, announced it closed a $105 million Series B funding round. This oversubscribed financing was led by TCGX and joined by other notable investors including, JP Morgan Life Sciences Private Capital, Samsara BioCapital, Marshall Wace, KB Investment, JPS Growth Investment Limited Partnership, and included support from Pathalys' founding investors, Catalys Pacific and DaVita Venture Group.